Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-189 first-line pembrolizumab plus pemetrexed/platinum in metastatic nonsquamous NSCLC
NL-OMON50379Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Started Aug 2016; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50379.